Cerus Corporation (CERS) key performance indicators and operating metrics (15 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Product Gross Margin | 52.00 percent | FY2026-Q1 |
| Government Contract Revenue | 6.2M | FY2026-Q1 |
| Platelet Kit Growth (Worldwide) | 10.00 percent | FY2026-Q1 |
| Gross Profit on Product Revenue | 27.9M | FY2026-Q1 |
| Product Revenue (North America) | 36.76M | FY2026-Q1 |
| Product Revenue (Europe, Middle East and Africa) | 15.68M | FY2026-Q1 |
| Change in Calculated Number of Treatable Platelet Doses (Worldwide) | 13.00 percent | FY2026-Q1 |
| Product Revenue (Other) | 1.23M | FY2026-Q1 |
| Product Revenue | 57.8M | FY2025-Q4 |
| Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization | 3.4M | FY2025-Q4 |
| Fibrinogen Complex Revenue (INTERCEPT Fibrinogen Complex) | 4.2M | FY2025-Q4 |
| Platelet Kit Growth (International) | 6.00 percent | FY2025-Q4 |
| Platelet Kit Growth (North America) | -3.00 percent | FY2025-Q4 |
| Change in Calculated Number of Treatable Platelet Doses (International) | 4.00 percent | FY2025-Q4 |
Back to CERS overview · CERS earnings · CERS holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.